IPO for Brainsway Ltd.

$11.00 (Est. Date 04/17/2019)

We are a commercial stage medical device company focused on the development and sale of non-invasive neuromodulation products using our proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology for the treatment of major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), for which we have received marketing authorization from the U.S. Food and Drug Administration (FDA). Deep TMS uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. Our proprietary electromagnetic coils, which we refer to as H-Coils, are designed to safely stimulate deep and broad brain regions, which we believe provides an advantage over other available TMS products, which we refer to collectively as Focal TMS, that generally use a "figure 8" design. We believe that our Deep TMS technology has the potential to be safe and effective for the treatment of a wide range of psychiatric, neurological and addiction disorders beyond MDD and OCD.

We are offering 2,500,000 American Depositary Shares, or the ADSs. Each ADS represents 2 of our ordinary shares. This is our initial public offering in the United States, and no public market currently exists in the United States for the ADSs. We have applied to list the ADSs on the Nasdaq Global Market, or Nasdaq, under the symbol "BWAY."

Show More
This information has been gathered from the company's offering prospectus.

IPO Documentation


Key IPO Data

2,500,000 ADS
Cantor Fitzgerald
This information has been gathered from the company's offering prospectus.

How Does an IPO Work?

Open a Motif Account

Open a brokerage account to get ready for trading.

Participate in an IPO

Review IPO pricing, prospectus, and other documentation.

Place a Conditional Order

Select an investment amount and fund the IPO.

Receive Your IPO Shares

View your allocated shares on account positions page.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date.